Aragen is a trusted partner for Small Molecule Drug Discovery (Synthetic chemistry/ medicinal chemistry/library chemistry coupled with biology (in vitro assay development & Screening, ADME and PK solutions and animal Pharmacology studies) as well as large Molecules to the global life sciences industry. From concept to commercial, we transform your ideas into solutions for better health.

Discovery Biology:
Optimization of drug-like properties and bioavailability measurements are assisted by a broad panel of in vitro ADME assays and PK studies in rodents and other relevant species. Additionally, we provide in vivo proof-of-concept through our animal pharmacology models in several therapeutic areas. Our exploratory (Non- GLP) toxicology and GLP in vitro toxicology studies provide early assessment of safety.

Reagent generation scientists provide reagent proteins and engineered cell lines to support multiple screening campaigns by our assay development and screening team.
Aragen has an experienced team of in vivo pharmacologists with strong domain knowledge in various animal models of disease to obtain in vivo proof-of-concept across multiple therapeutic areas. We have over 60 validated models in Oncology, Inflammation, Autoimmune Disease, Pain, Fibrosis, Cardiovascular and Metabolic Diseases. Our screening modalities include small molecules, large molecules and antibodies. We follow acute, chronic, mechanistic and pharmacodynamic models to assess target engagement, efficacy, PK/PD correlation and biomarker evaluation, in collaboration with our in vitro pharmacology and DMPK teams. Our state-of-the-art vivarium and agile operational model enable quick allocation of appropriate space with technical staff to accelerate research programs. We provide specialized platforms and technical expertise, including ex vivo/in vitro testing, clinical pathology and histopathology and histological preparations. In addition to disease models in a multitude of therapeutic areas, we also undertake non-GLP pharmacokinetic (PK), pharmacodynamic (PD), and toxicology screens.

Integrated Drug Discovery:
Our dedicated multidisciplinary team – comprising talented medicinal, synthetic and computational chemists, biologists, pharmacologists, process development and formulation scientists – offers a unified strategy to advance customer programs through critical decision milestones. Speed, scientific rigor, flexibility and data integrity are key Aragen differentiators.

Every integrated discovery program is assigned a project lead from chemistry and biology respectively, closely monitored by their department heads. The size and composition of our scientific teams are customized based on program needs/stage and timelines. To address specific program challenges, expertise in chemistry and biology can be accessed from our larger talent pool, on need basis.
Discovery Chemistry:
With India’s largest chemistry services talent pool, we are the industry leader in offering discovery chemistry solutions. Our expertise includes peptides, nucleosides, nucleotides, carbohydrates, protein degraders, organoboranes, organometallics and lipids. Our flexible business model (FTE or FFS), with access to diverse skillsets, enables us to customize the size and composition of our teams, at short notice, to meet customer project objectives. Aragen computational chemists bring strong knowledge in informatics and artificial intelligence to accelerate virtual screening for identification of hits on therapeutic targets. Leveraging various customized data analytical tools and techniques, we provide better understanding of structural activity relationship (SAR), which leads to faster candidate selection.

Scale up and Manufacturing:
Small Molecules: Aragen provides end-to-end solutions that accelerate your molecule from concept to commercial. Whether you engage us in early or late phase; require milligram quantities for discovery to hundreds of kilograms for commercial supply, we raise the bar on successful outcomes of your small molecule programs.

Our digital project management platform provides customers real time access to the status of their chemistry projects. Project management tools like eProcurement, eSynthesis, eSample, eCuleNote and eCPORTAL offer key metrics on operational excellence, driving the successful outcomes of discovery programs.

Large Molecules

Aragen supports NBE’s & Biosimilars Cell Line Development, Bioproduction (Upstream, Downstream process development), Molecular Biology, Analytics, Antibody discovery and Preclinical Efficacy testing. Aragen also have few clones for out-licensing.

• Cell line Development : Delivering commercial-quality cell lines
• Royalty-free CHO DG44 expression platform with regulatory experience – standard antibody CLD 5 g/L in ~5 months
• Innovative CHO platform that builds on the GS system to enable a step-change in CLD
• Experience with diverse CHO expression systems, e.g. GS, antibiotics, ProteoNic, etc.
• Clonality expertise
• IND-ready packages
• CHO DG44, CHO GS (ASIMOV, CHOZN), SP2/0, NS0 etc..,
• Clones available (Biosimilars) : We also have following clones i.e Bevacizumab, Adalimumab, Infliximab and Trastuzumab which are readily available for short term (1 year to 5 years) and long term (perpetual) licensing (Non exclusivity for in house research) and exclusivity (for market production).
• Protein production : Design, create, transfect and purify reagents, antigens, and therapeutics
• Upstream and Downstream process development
• Antibody Discovery : Industry-leading Hybridoma techniques for accelerated screens
• Analytics : Aragen takes a holistic approach to developability assessment and formulation studies
• Innovative CHO expression platform to enable a step-change in CLD
• Diverse pool of 75 independent GS KO clones with full cGMP banking and ICH Q5 testing
• Robust growth across a panel of commercial media
• Covid – 19 : Generation of reagents/antibodies required for testing of novel corona virus in qPCR or lateral flow/ELISA assays. We also have experience generating cell lines producing vaccine candidates for Covid-19”